Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

ID DOID:9513
Name plasma cell leukemia
Definition A plasma cell neoplasm that is characterized by the presence of a circulating clonal plasma cell count that exceeds 2x10^9/L or is 20% of the leukocyte differential count.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer lymphoma non-Hodgkin lymphoma B-cell lymphoma mature B-cell neoplasm plasma cell neoplasm plasma cell leukemia

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03441958 Phase Ib/II Cyclophosphamide + ECT-001 cord blood cells + Fludarabine + Mycophenolate mofetil + Tacrolimus ECT-001 (UM171) Expanded Cord Blood Transplant to Treat High-risk Multiple Myeloma Active, not recruiting CAN 0
NCT05208307 Phase II belantamab mafodotin-blmf + Dexamethasone + Pomalidomide Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma Recruiting USA 0
NCT05823571 Phase I Itacitinib Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Recruiting USA 0
NCT06066359 Phase Ib/II Cyclophosphamide + Fludarabine + NY-ESO-1 TCR/IL-15 NK Phase I/II Trial of Cord Blood-Derived NK Cells Genetically Engineered With NY-ESO-1 TCR/IL-15 Cell Receptor for Relapsed/Refractory Multiple Myeloma Recruiting USA 0
NCT06517017 Phase II Dexamethasone + Isatuximab + Lenalidomide Use of Isatuximab, Dexamethasone and Lenalidomide in a Go-Slow Fashion for Ultra-Frail Patients With Multiple Myeloma (UltraFrailMM) Not yet recruiting USA 0
NCT06636552 Phase II Daratumumab Bortezomib + Cyclophosphamide + Daratumumab + Dexamethasone An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L (EUMELEIA) Recruiting GRC 0